Venus Medtech introduces Endoluminal Sciences’ active anti-paravalvular leak technology

Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as "Venus Medtech"), a leading transcatheter heart valve medical device company in China,announced cooperation with Endoluminal Sciences Pty Ltd. (hereinafter referred to as "Endoluminal Sciences"), a global leader in transcatheter solutions for structural heart disease, to introduce Endoluminal Sciences’ active anti-paravalvular leak technology to China and incorporate it to Venus Medtech’s next-generation TAVR products.

Transcatheter aortic valve replacement (TAVR) is a pioneering therapy for the treatment of aortic valve stenosis that implants a prosthetic heart valve without the need for thoracotomy. As a major risk in TAVR, perivalvular leak (PVL) predisposes patients to heart failure and death and is a key factor in increased postoperative mortality. Therefore, reducing PVL is crucial for the long-term success of TAVR.

Endoluminal Sciences has developed a novel active anti-paravalvular leak technology based on its proprietary expandable polymer-based technology. Unlike traditional anti-PVL solutions, this technology can actively reduce PVL in transcatheter heart valve prostheses. This intelligent anti-PVL technology provides active sealing of the devices in complex anatomy while enabling a low delivery profile. The technology is designed to be easily adaptable to current endovascular implants enabling the retention of their durability and deliverability characteristics It is expected to provide best-in-class PVL prevention for patients receiving TAVR.

On this cooperation, Professor Horst Sievert, an expert on Venus Medtech’s Global Advisor Board and Director of CardioVascular Center Frankfurt, Germany, said, "As TAVR moves into a potentially younger population, the long-term risk of PVL comes to the fore. Endoluminal Sciences’ technology offers a targeted advancement to the TAVR products of Venus Medtech."


Eric Zi, CEO of Venus Medtech, said, "By integrating the active anti-VPL technology of Endoluminal Sciences into our next-generation TAVR product pipelines, Venus Medtech will maintain its leadership in the global market and continue to improve the clinical outcomes. The effective anti-VPL solution with enhanced safety of operation will bring new hopes to patients in the fast-growing Chinese TAVR market."


Ashish Mitra, CEO of Endoluminal Sciences, said, "We are excited to partner with the Venus Medtech team to build their next generation TAVR products with the Endoluminal Sciences’ technology. Being the market leader in China, Venus Medtech offers us the best platform to extend our technology to TAVR patients in China. "

Prev:VenusA-Plus retrievable transcatheter aortic valve replacement system obtains quick approv···

Next:NMPA approves key laboratory jointly established by Venus Medtech